Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis.

Li L, Zhong Y, Zhang H, Yu H, Huang Y, Li Z, Chen G, Hua X.

Mol Clin Oncol. 2017 Jul;7(1):76-80. doi: 10.3892/mco.2017.1259. Epub 2017 May 12.

2.

Age-associated prognostic and predictive biomarkers in patients with breast cancer.

Kolečková M, Kolář Z, Ehrmann J, Kořínková G, Trojanec R.

Oncol Lett. 2017 Jun;13(6):4201-4207. doi: 10.3892/ol.2017.6000. Epub 2017 Apr 6.

3.

Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.

Begg CB, Rice MS, Zabor EC, Tworoger SS.

Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23.

PMID:
28334730
4.

Understanding breast cancer - The long and winding road.

Lukong KE.

BBA Clin. 2017 Jan 27;7:64-77. doi: 10.1016/j.bbacli.2017.01.001. eCollection 2017 Jun. Review.

5.

Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.

Kochel TJ, Reader JC, Ma X, Kundu N, Fulton AM.

Oncotarget. 2017 Jan 24;8(4):6540-6554. doi: 10.18632/oncotarget.14145.

6.

Clinicopathological Study of Triple Negative Breast Cancers.

Ishitha G, Manipadam MT, Backianathan S, Chacko RT, Abraham DT, Jacob PM.

J Clin Diagn Res. 2016 Sep;10(9):EC05-EC09. Epub 2016 Sep 1.

7.

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.

Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, Rouzier R, Faure C, Garbay JR, Daraï E, Hudry D, Gimbergues P, Villet R, Lambaudie E.

Br J Cancer. 2016 Oct 25;115(9):1024-1031. doi: 10.1038/bjc.2016.283. Epub 2016 Sep 29.

PMID:
27685443
8.

The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.

Johnston R, D'Costa Z, Ray S, Gorski J, Harkin DP, Mullan P, Panov KI.

Oncotarget. 2016 Oct 18;7(42):68097-68110. doi: 10.18632/oncotarget.11770.

9.

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.

Zhang P, Yin Y, Mo H, Zhang B, Wang X, Li Q, Yuan P, Wang J, Zheng S, Cai R, Ma F, Fan Y, Xu B.

Oncotarget. 2016 Sep 13;7(37):60647-60656. doi: 10.18632/oncotarget.10607.

10.

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Dai X, Xiang L, Li T, Bai Z.

J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016. Review.

11.

Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer.

Liang Z, Bian X, Shim H.

Biochem Biophys Res Commun. 2016 Aug 26;477(3):461-6. doi: 10.1016/j.bbrc.2016.06.076. Epub 2016 Jun 16.

PMID:
27318091
12.

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.

Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P, Wang Z.

Diagn Pathol. 2016 Apr 26;11:41. doi: 10.1186/s13000-016-0491-5.

13.

The Role of PIWIL4, an Argonaute Family Protein, in Breast Cancer.

Wang Z, Liu N, Shi S, Liu S, Lin H.

J Biol Chem. 2016 May 13;291(20):10646-58. doi: 10.1074/jbc.M116.723239. Epub 2016 Mar 8.

14.

Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC.

Am J Transl Res. 2015 Jun 15;7(6):1009-20. eCollection 2015.

15.

Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer.

Liu J, Xiao Y, Wei W, Guo JX, Liu YC, Huang XH, Zhang RX, Wu YJ, Zhou J.

Exp Ther Med. 2015 Jul;10(1):379-385. Epub 2015 May 12.

16.

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.

Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V.

PLoS One. 2015 Jun 3;10(6):e0128368. doi: 10.1371/journal.pone.0128368. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132647.

17.

Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.

Chen C, Li Z, Yang Y, Xiang T, Song W, Liu S.

Cancer Biol Ther. 2015;16(6):856-65. doi: 10.1080/15384047.2015.1040957.

19.

Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors.

Barquet-Muñoz SA, Villarreal-Colin SP, Herrera-Montalvo LA, Soto-Reyes E, Pérez-Plasencia C, Coronel-Martínez J, Pérez-Montiel D, Vázquez-Romo R, Cantú de León D.

BMC Cancer. 2015 Feb 20;15:75. doi: 10.1186/s12885-015-1079-2.

20.

Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model.

Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X, Li Y, Jie H, Liu C, Xiong Y, Zuo Z, Zeng A, Li Y, Yu L, Shen G, Wang D, Xie Y, Ye T, Wei Y.

Cell Death Dis. 2015 Mar 26;6:e1701. doi: 10.1038/cddis.2015.63.

Supplemental Content

Support Center